Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Triclofos. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | TPI1 | P60174 | 2/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | PGK2 | P07205 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PGD | P52209 | 2/20 | 0.31 |
| ▸ | MPI | P34949 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triclofos SCHEMBL125854 | 0.97 | FBP1 (0.38) | FBP1TPI1LPAR3LPAR2LPAR1 | |
| Triclofos SCHEMBL27912874 | 0.86 | S1PR1 (0.33) | FBP1TPI1 | |
| SCHEMBL3176347 | 0.81 | TSHR (0.33) | KDM4ECYP2C19KMT2A | |
| Triclofos SCHEMBL28702793 | 0.81 | FBP1 (0.33) | FBP1LPAR3LPAR2LPAR1 | |
| Triclofos SCHEMBL10494633 | 0.81 | FDPS (0.37) | PGK1PGK2FDPSTDP1 | |
| Triclofos SCHEMBL16824084 | 0.80 | LPAR3 (0.46) | LPAR3LPAR2LPAR1 | |
| SCHEMBL4995915 | 0.79 | KDM4E (0.31) | TDP1KDM4ECYP2C19KMT2A | |
| SCHEMBL31114338 | 0.79 | PGK1 (0.38) | FBP1TPI1LPAR3LPAR2LPAR1 | |
| SCHEMBL27754463 | 0.78 | FDPS (0.39) | FDPSBLMTDP1 | |
| Triclofos SCHEMBL10665197 | 0.78 | TRIM24 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 518 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200187851-A1 | PERIODONTAL DISEASE STRATIFICATION AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2020-06-18 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060014697-A1 | Pharmaceutical compositions for prevention of overdose or abuse | SHIRE LLC | 2006-01-19 | — | — | US | claimed |
| US-20040058946-A1 | Abuse-resistant prodrugs of oxycodone and other pharmaceuticals | COLLEGIUM PHARMACEUTICAL, INC. | 2004-03-25 | — | — | US | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| JP-8301312-A | — | — | None | — | — | JP | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-0472969-A1 | External preparation comprising calcium silicate | Eisai Co., Ltd. (JP) | 1992-03-04 | — | — | EP | disclosed |
| EP-0388954-A2 | Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions | FMC Corporation (US) | 1990-09-26 | — | — | EP | disclosed |
| EP-0182765-A2 | Electrochemical controlled release drug delivery system | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1986-05-28 | — | — | EP | disclosed |
| US-4585652-A | REDOX SITES ON CHARGED POLYMER | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1986-04-29 | — | — | US | disclosed |
| US-4423038-A | Phosphoryl compounds, pharmaceutical preparations containing such compounds, and their use | CIBA-GEIGY CORPORATION (US) | 1983-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058946-A1 | Abuse-resistant prodrugs of oxycodone and other pharmaceuticals | OPRK1, OPRM1, OPRL1 | FBP1 2233/4885TPI1 2281/4885LPAR3 1591/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | FBP1 3888/4885TPI1 3191/4885LPAR3 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.